MicrodosingSchizophreniaSubstance Use Disorders (SUD)Psilocybin

Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice

In mice, a single dose of psilocybin markedly altered the prefrontal cortex transcriptome but produced no acute or durable changes in food intake, body weight or metabolic outcomes in diet-induced or genetic obesity models, and neither sub‑chronic microdosing nor combination with GLP‑1 enhanced weight loss; a high dose reduced sucrose preference but did not curb binge‑like eating. These preclinical results argue against psilocybin as a weight‑lowering therapy, though limitations of rodent models mean human studies may still be needed to capture possible nuances.

Authors

  • Gitte Knudsen

Published

Translational Psychiatry
individual Study

Abstract

Psilocybin and other serotonergic psychedelics have re-emerged as therapeutics for neuropsychiatric disorders, including addiction. Psilocybin induces long-lasting effects on behavior, likely due to its profound ability to alter consciousness and augment neural connectivity and plasticity. Impaired synaptic plasticity in obesity contributes to ‘addictive-like’ behaviors, including heightened motivation for palatable food, and excessive food seeking and consumption. Here, we evaluate the effects of psilocybin on feeding behavior, energy metabolism, and as a weight-lowering agent in mice. We demonstrate that a single dose of psilocybin substantially alters the prefrontal cortex transcriptome but has no acute or long-lasting effects on food intake or body weight in diet-induced obese mice or in genetic mouse models of obesity. Similarly, sub-chronic microdosing of psilocybin has no metabolic effects in obese mice and psilocybin does not augment glucagon-like peptide-1 (GLP-1) induced weight loss or enhance diet-induced weight loss. A single high dose of psilocybin reduces sucrose preference but fails to counter binge-like eating behavior. Although these preclinical data discourage clinical investigation, there may be nuances in the mode of action of psychedelic drugs that are difficult to capture in rodent models, and thus require human evaluation to uncover.

Available with Blossom Pro

Research Summary of 'Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice'

Introduction

Fadahunsi and colleagues frame obesity and addictive disorders as conditions that share neurobiological substrates, including persistent alterations in synaptic plasticity and reward-circuit dysfunction that can drive compulsive consumption. The serotonin system, and specifically signaling at the 5-HT2A receptor activated by psilocybin's metabolite psilocin, is implicated in both appetite regulation and neural plasticity; earlier preclinical and self-report data hinted that classic psychedelics might reduce consumption of rewarding substances or foods and thereby have therapeutic potential for disordered eating or obesity. Against this background, the study set out to evaluate whether psilocybin alters feeding behaviour, energy metabolism, body weight, or related transcriptional programmes in mice. The investigators tested acute and sub-chronic dosing regimens across multiple mouse models — diet-induced obese (DIO) mice, genetic obesity models (ob/ob and MC4R knockout mice), and an intermittent high-fat diet model that produces binge-like eating — and they profiled brain gene expression in the prefrontal cortex (PFC) and hypothalamus at 3 hours and 4 weeks after a single dose to probe both immediate and longer-term molecular effects.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (13)

Papers cited by this study that are also in Blossom

Psychedelic Psychiatry’s Brave New World

Nutt, D. J., Erritzoe, D., Carhart-Harris, R. L. · Cell (2020)

Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels

Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)

Psychedelics promote structural and functional neural plasticity

Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)

Associations between lifetime classic psychedelic use and markers of physical health

Simonsson, O., Sexton, J. D., Hendricks, P. S. · Journal of Psychopharmacology (2021)

65 cited
Cessation and reduction in alcohol consumption and misuse after psychedelic use

Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)

211 cited
Acute effects of lysergic acid diethylamide in healthy subjects

Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)

Microdosing psychedelics: personality, mental health, and creativity differences in microdosers

Anderson, T., Petranker, R., Rosenbaum, D. et al. · Psychopharmacology (2019)

142 cited
Powerful substances in tiny amounts An interview study of psychedelic microdosing

Johnstad, P. G. · Nordic Studies on Alcohol and Drugs (2018)

121 cited
Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder

Doss, M. K., Považan, M., Rosenberg, M. D. et al. · Translational Psychiatry (2021)

249 cited
Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

Show all 13 references
Psilocybin and LSD Have No Long-Lasting Effects in an Animal Model of Alcohol Relapse

Meinhardt, M. W., Güngör, C., Skorodumov, I. et al. · Neuropsychopharmacology (2020)

Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism

Barroso Flores, J., Hoffmann, R., Wagner, K. et al. · Science Advances (2021)

Cited By (5)

Papers in Blossom that reference this study

An open-label pilot study of psilocybin-assisted therapy for binge eating disorder

Dallery, J., Miller, J. L., Boissoneault, J. et al. · Journal of Eating Disorders (2026)

Psilocybin treatment extends cellular lifespan and improves survival of aged mice

Kato, K., Kleinhenz, J. M., Shin, Y. J. et al. · npj Aging (2025)

A multi-institutional investigation of psilocybin's effects on mouse behavior

Lu, O. D., White, K., Raymond, K. et al. · Biorxiv (2025)

5-Methoxy-2-aminoindane Reverses Diet-Induced Obesity and Improves Metabolic Parameters in Mice: A Potential New Class of Antiobesity Therapeutics

Baraghithy, S., Gammal, A., Permyakova, A. et al. · ACS Pharmacology and Translational Science (2024)

Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action

Cameron, L. P., Benetatos, J., Lewis, V. et al. · Journal of Neuroscience (2023)

45 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.